BIOMARKER:

BRCA1 mutation

News alerts, weekly reports and conference planners

Entrez ID:

672

Related biomarkers:

‹

›

BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	rucaparib Sensitive: A1 - Approval ASCO.org - 3 days (New A2) rucaparib Sensitive : A1 ASCO.org - 3d	rucaparib Sensitive: A1 - Approval ASCO.org - 3 days rucaparib Sensitive : A1 ASCO.org - 3 days - (New A2)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib Sensitive: A1 - Approval ASCO.org - 3 days (New A2) olaparib Sensitive : A1 ASCO.org - 3d	olaparib Sensitive: A1 - Approval ASCO.org - 3 days olaparib Sensitive : A1 ASCO.org - 3 days - (New A2)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	niraparib Sensitive: A1 - Approval ASCO.org - 3 days (New A2) niraparib Sensitive : A1 ASCO.org - 3d	niraparib Sensitive: A1 - Approval ASCO.org - 3 days niraparib Sensitive : A1 ASCO.org - 3 days - (New A2)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	BAY 1895344 Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks (New C4) BAY 1895344 Sensitive : C3 IGCS 2022 - 2wk	BAY 1895344 Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks BAY 1895344 Sensitive : C3 IGCS 2022 - 2 weeks - (New C4)
BRCA1 mutation	Pancreatic Cancer	BRCA1 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) olaparib Sensitive : A1 ESMO 2022 - 3wk	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks olaparib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) olaparib Sensitive : A1 ESMO 2022 - 3wk	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks olaparib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation	Solid Tumor	BRCA1 mutation	Solid Tumor	olaparib Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) olaparib Sensitive : C1 ESMO 2022 - 3wk	olaparib Sensitive: C1 - Off-label ESMO 2022 - 3 weeks olaparib Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	bevacizumab + olaparib + durvalumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) bevacizumab + olaparib + durvalumab Sensitive : C2 ESMO 2022 - 3wk	bevacizumab + olaparib + durvalumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks bevacizumab + olaparib + durvalumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation	Peritoneal Cancer	BRCA1 mutation	Peritoneal Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
BRCA1 mutation	Peritoneal Cancer	BRCA1 mutation	Peritoneal Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA1 mutation	Fallopian Tube Cancer	BRCA1 mutation	Fallopian Tube Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA1 mutation	Fallopian Tube Cancer	BRCA1 mutation	Fallopian Tube Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
BRCA1 mutation	Peritoneal Cancer	BRCA1 mutation	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA1 mutation	Fallopian Tube Cancer	BRCA1 mutation	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA1 mutation	Fallopian Tube Cancer	BRCA1 mutation	Fallopian Tube Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation	Peritoneal Cancer	BRCA1 mutation	Peritoneal Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
BRCA1 mutation	Fallopian Tube Cancer	BRCA1 mutation	Fallopian Tube Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA1 mutation	Peritoneal Cancer	BRCA1 mutation	Peritoneal Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
BRCA1 mutation	Pancreatic Adenocarcinoma	BRCA1 mutation	Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	bevacizumab Resistant: A2 - Guideline bevacizumab Resistant : A2	bevacizumab Resistant: A2 - Guideline bevacizumab Resistant : A2
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2

BRCA1 mutation

Associations